ライフサイエンスコーパス: calpain inhibitor

1 ase in expression of calpastatin (endogenous calpain inhibitor).

2 mined at high concentrations in vitro by the calpain inhibitor.

3 overexpression of calpastatin, an endogenous calpain inhibitor.

4 ng apoptosis was significantly retarded by a calpain inhibitor.

5 also significantly increased (P < 0.05) with calpain inhibitor.

6 vented by calpastatin, a naturally occurring calpain inhibitor.

7 select for resistance to this cell-permeant calpain inhibitor.

8 d 4) mechanical ventilation with a selective calpain inhibitor.

9 ceptors; both effects were also blocked by a calpain inhibitor.

10 spase inhibitor but not by the proteosome or calpain inhibitor.

11 slices was prevented by a membrane-permeable calpain inhibitor.

12 agmatic levels of calpastatin, an endogenous calpain inhibitor.

13 e intracellular Ca2+ chelator but not by the calpain inhibitor.

14 gn of cyclic peptides and peptidomimetics as calpain inhibitors.

15 pha processing was blocked by proteasome and calpain inhibitors.

16 d preservation in the presence or absence of calpain inhibitors.

17 Cleavage was inhibited by calpain inhibitors.

18 ely proteasome-independent, but sensitive to calpain inhibitors.

19 respectively) was limited with any of these calpain inhibitors.

20 egulated by distinct doses of proteasome and calpain inhibitors.

21 eolysis occurs in a manner sensitive only to calpain inhibitors.

22 xide 1h (IC50 = 0.35 microM) are also potent calpain inhibitors.

23 ased by about 50%, an effect also blocked by calpain inhibitors.

24 ctivity as well as evaluating the effects of calpain inhibitors.

25 nto smaller fragments was totally blocked by calpain inhibitors.

26 Activation is prevented by calpain inhibitors.

27 n be inhibited by calcium chelators and some calpain inhibitors.

28 D1 protein that was completely reversible by calpain inhibitors.

29 to classic electrophilic "warheads" in known calpain inhibitors.

30 on, but this inhibition could be reversed by calpain inhibitors.

31 st PPADS, the calcium chelator BAPTA-AM, and calpain inhibitors.

32 tive form required Ca(2+) and was blocked by calpain inhibitors.

33 lpain substrate, was modulated by Ca(2+) and calpain inhibitors.

34 dent on calpains, such that it is blocked by calpain inhibitors.

35 on, which was completely blocked by MAPK and calpain inhibitors.

36 ketoesters was synthesized and studied as mu-calpain inhibitors.

37 tenuated by buffering [Ca2+]i and blocked by calpain inhibitors.

38 rons, which was largely blocked by selective calpain inhibitors.

39 rs when added to osteoclasts pretreated with calpain inhibitors.

40 ells by up-regulating endogenous caspase and calpain inhibitors.

41 The calpain inhibitor (2)-3-(4-iodophenyl)-2-mercapto-2-prop

42 nous protease which is inhibited by specific calpain inhibitors; 3.

43 The calpain inhibitor A-705253 (3-10 mg/kg) was tested in a

44 generation of p29 was Ca(2+)-dependent, and calpain inhibitors abolished p29 production.

45 Addition of calpain inhibitors after BDNF or TEA treatment maintaine

46 ies was substantially delayed by addition of calpain inhibitors after sublethal excitotoxic exposure.

47 n this study, we evaluated the effect of the calpain inhibitor AK295 [Z-Leu-aminobutyric acid-CONH(CH

48 of calpains with the peptide alpha-ketoamide calpain inhibitor AK295 can reduce the clinical and path

49 Pretreatment with both the calpain inhibitor ALLN (N-acetyl-Leu-Leu-norleucinal) an

50 the cysteine protease inhibitor E-64 or the calpain inhibitor ALLN (N-acetyl-leucyl-leucyl-norleucin

51 Calpain inhibitor ALLN induced VEGFR2 activation, which

52 ion-induced immobilization is prevented by a calpain inhibitor and by an allosteric LFA-1 inhibitor.

53 Data suggests CYGAK may be a P' calpain inhibitor and may achieve its specificity throug

54 (CYGAK)(2) is the first P' specific calpain inhibitor and will be a valuable tool to prevent

55 rption in a manner similar to the effects of calpain inhibitors and had no further effect on these pa

56 d breast cancer cells that was reversible by calpain inhibitors and not by phenylmethylsulfonyl fluor

57 romolar range, rivaling other peptidomimetic calpain inhibitors and presenting an improved selectivit

58 sults indicate that MP acts as a proteinase (calpain) inhibitor and define a new mechanism for its ac

59 The mRNA levels of calpastatin (endogenous calpain inhibitor) and beta-actin (house-keeping) genes

60 bitors (peptidomimetic and natural product), calpain inhibitors, and anti-PgPM4 monoclonal antibodies

61 xazolyl-propionic acid receptor antagonists, calpain inhibitors, and cyclosporine A analogues.

62 rs, including three GSK3beta inhibitors, two calpain inhibitors, and one adenylyl cyclase activator,

63 h is sensitive to wortmannin (IC50 7 nM) and calpain inhibitors, and the phosphorylation of PtdIns3P

64 om P3 rats were used to test the efficacy of calpain inhibitors as otoprotective molecules.

65 Greater sensitivity of HT-29 cells to a calpain inhibitor, as measured by IL-8 secretion, sugges

66 e positive CD4(+) thymocytes, not only did a calpain inhibitor augment CD3-induced proliferation, but

67 protease inhibitor, and the highly specific calpain inhibitor BDA-410 restored normal synaptic funct

68 raperitoneal administration of the selective calpain inhibitor benzyloxycarbonyl-leucyl-leucinal (5 m

69 Moreover, calpain inhibitors blocked the ischaemia-induced depress

70 Calpain inhibitors blocked these changes.

71 e receptor into the cell culture medium, and calpain inhibitors blocked this effect.

72 of C6 cells with calpeptin (a cell-permeable calpain inhibitor) blocked calpain overexpression, MAG d

73 Calpeptin, a cell-permeable calpain inhibitor, blocked both Erk1,2 activation and ne

74 etreatment of Jurkat cells with calpeptin, a calpain inhibitor, blocked PTP1B cleavage and inhibited

75 lencing; however, it could be prevented with calpain inhibitors, calcium-chelating agents, calpain kn

76 rt-term (4-h) exposure to the cell-permeable calpain inhibitors calpain inhibitor II and E-64-d incre

77 cular endothelial cell monolayers exposed to calpain inhibitors (calpain inhibitor III and calpastati

78 Three calpain inhibitors, calpain inhibitor I, MDL-28170, and

79 In contrast to proteasomal inhibitors, the calpain inhibitor calpastatin and the lysosomal inhibito

80 Transient expression of the specific calpain inhibitor calpastatin blocked the loss of p107 p

81 Transient expression of the calpain inhibitor calpastatin increased cyclin D1 protei

82 Overexpression of the calpain inhibitor calpastatin or eIF4G1 resulted in incr

83 yR antagonists ryanodine and dantrolene, the calpain inhibitor calpastatin, and by a specific inhibit

84 calpeptin, overexpression of the endogenous calpain inhibitor calpastatin, or gene silencing of calp

85 of either m- or mu-calpain or the endogenous calpain inhibitor calpastatin.

86 proteases and down-regulated the endogenous calpain inhibitor calpastatin.

87 regulated the caspase inhibitor FLIP and the calpain inhibitor calpastatin.

88 lled by a marked depletion of the endogenous calpain inhibitor, calpastatin (CAST), from AD neurons,

89 es showed increased levels of the endogenous calpain inhibitor, calpastatin (CAST).

90 on, whereas overexpression of the endogenous calpain inhibitor, calpastatin, attenuated Ox-LDL-induce

91 alpains and overexpression of the endogenous calpain inhibitor, calpastatin, prevent the production o

92 lt of the marked depletion of the endogenous calpain inhibitor, calpastatin.

93 lation-induced degradation of the endogenous calpain inhibitor, calpastatin.

94 rn indicative of calpain activation, and the calpain inhibitor calpeptin abrogated SAHA-induced cell

95 Indeed, the calpain inhibitor calpeptin and the removal of the calpa

96 Pretreatment with the calpain inhibitor calpeptin blocked calpain activation a

97 retreatment of HL-60 cells with the specific calpain inhibitor calpeptin effectively blocked both dru

98 Treatment of MEL cells with the specific calpain inhibitor calpeptin increased the levels of USF

99 The calpain inhibitor calpeptin increased WASP levels in act

100 Interestingly, treatment with the calpain inhibitor calpeptin, overexpression of the endog

101 um-dependent and was blocked by the specific calpain inhibitor calpeptin.

102 died possible neuroprotective effects of the calpain inhibitors calpeptin and calpain inhibitor V.

103 ffect was much less than that exerted by the calpain inhibitors calpeptin and/or E64-d.

104 The peptidyl calpain inhibitors calpeptin, MDL 28,170 (MDL) and E64d

105 received daily intraperitoneal injections of calpain inhibitor (calpeptin) or vehicle from day 1 unti

106 d by the PI3K inhibitor, wortmannin, and the calpain inhibitor, calpeptin, constituting the first evi

107 se hamster ovary cells were decreased by the calpain inhibitor, calpeptin, or the highly specific cal

108 In addition, preincubation with the calpain inhibitor, calpeptin, suppressed the accumulatio

109 1 subunits were significantly reduced by the calpain inhibitor, calpeptin.

110 d from this animal model of SCI suggest that calpain inhibitor can provide neuroprotection in patient

111 ssive depletion; we show here that selective calpain inhibitors can block this step, which suggests t

112 Calpain inhibitors can protect against necrotic neuronal

113 hesions or stress fibers) in the presence of calpain inhibitors; cells expressing constitutively acti

114 ing the EGFP-ataxin-3-84Q zebrafish with the calpain inhibitor compound calpeptin decreased levels of

115 und that treating the MJD zebrafish with the calpain inhibitor compound calpeptin produces complete r

116 Previous work using calpain inhibitor CYLA in our laboratory showed signific

117 cell receptor-stimulated murine thymocytes, calpain inhibitors decreased cleavage of gammac.

118 cTnT-ND in myocardial ischemia reperfusion, calpain inhibitors decreased the level of cTnT-ND in Tri

119 Experimental treatments with caspase 3 or calpain inhibitors demonstrated that PV IgGs induced aca

120 ddition, I-benzyl-CH=C(SH)COOH (PD150606), a calpain inhibitor directed toward the calcium binding si

121 Calpain inhibitors disrupted the podosome belt, blocked

122 T3, prostate, and breast cancer cells with a calpain inhibitor dramatically increased the half-life o

123 pain activity which can be attenuated by the calpain inhibitor E-64-d.

124 ydrazine, KCl, quinine, merocyanine 540, the calpain inhibitor E-64d, and the scramblase inhibitor R5

125 pan-caspase inhibitor z-VAD-fmk, but not the calpain inhibitor E-64d, prevents Bid cleavage, Bax conf

126 The calpain inhibitor E64-d or the lysosomal protease inhibi

127 he absence of calcium and in the presence of calpain inhibitors (E64c, PD 150606 and calpastatin).

128 Calpain inhibitors elicited effects at concentrations of

129 knowledge, this study is the first to use a calpain inhibitor following brain trauma and suggests th

130 pase-2 down-regulation by rottlerin, whereas calpain inhibitor had no effect.

131 pastatin peptide and PD150606, two selective calpain inhibitors, had no effect on BRCA1 stability, wh

132 dysfunction, all of which were attenuated by calpain inhibitor I (10 mg/kg i.p.), administered 30 min

133 s completely inhibited by preincubation with calpain inhibitor I (N-acetyl-leucyl-leucyl-norleucinal

134 h ubiquitin-dependent proteasome inhibitors: calpain inhibitor I and lactacystin each prevented this

135 bited by the addition of protease inhibitors calpain inhibitor I and N-tosyl-phechloromethyl ketone a

136 by pharmacological inhibitors (calpeptin and calpain inhibitor I and PD98059, respectively) for EGF-i

137 muscle cells (activated with endotoxin) with calpain inhibitor I attenuated the binding of activated

138 whereas complete inhibition is observed with calpain inhibitor I but not with the proteasome inhibito

139 Here we investigate the effects of calpain inhibitor I on the organ injury (kidney, liver,

140 As anticipated, pretreatment with calpain inhibitor I prevented the proteolytic degradatio

141 rovide evidence that the mechanisms by which calpain inhibitor I reduces the circulatory failure as w

142 ain inhibitors N-acetyl-leu-leu-norleucinal (calpain inhibitor I) and carbenzoxy-val-phe-H (MDL 28,17

143 and N-acetyl-leucinyl-leucinyl-norleucinal (calpain inhibitor I) were found to inhibit the CL activi

144 Our results indicate that calpain inhibitor I, calpain inhibitor II, and leupeptin

145 addition of protease inhibitors, leupeptin, calpain inhibitor I, E-64, or pepstatin (0.5 mM each) to

146 Sulfasalazine and calpain inhibitor I, inhibitors of NF-kappaB activation,

147 The cell permeant agent, calpain inhibitor I, limited EGF-induced motility and de

148 Three calpain inhibitors, calpain inhibitor I, MDL-28170, and PD150606, but not th

149 s as nifedipine, verapamil and diltiazem, by calpain inhibitor I, or by the intracellular calcium che

150 Lactacystin and calpain inhibitor I, specific inhibitors of the 26S prot

151 which could be blocked by pretreatment with calpain inhibitor I.

152 e activity, in NIH3T3 cells was inhibited by calpain inhibitors I and II or the p38 MAP kinase inhibi

153 ddition of the calpain inhibitors MDL28,170, calpain inhibitors I and II, and leupeptin (all 1-100 mi

154 in YY1 protein levels could be prevented by calpain inhibitor II and calpeptin.

155 scle strips and adipocytes, exposure to both calpain inhibitor II and E-64-d reduced insulin-mediated

156 Calpain inhibitor II similarly blocked formation of the

157 y TCDD, whereas the protease inhibitors EST, calpain inhibitor II, and chloroquine do not affect this

158 r results indicate that calpain inhibitor I, calpain inhibitor II, and leupeptin all provided signifi

159 Calpain inhibition via calpain inhibitor III and calpastatin decreased IL-1beta

160 ll monolayers exposed to calpain inhibitors (calpain inhibitor III and calpastatin) or transfected wi

161 eridine propranol and were partly blocked by calpain inhibitor III but were not affected by the NR2A-

162 murine L cells, treatment with calpeptin or calpain inhibitor III increased Abeta42, but not Abeta40

163 and Abeta42 prompted us to determine how the calpain inhibitor III MDL 28170 influences these three c

164 inhibitor of calcium/calmodulin kinase, and calpain inhibitor III, a calpain inhibitor, inhibited NM

165 ibiting the activation of calpain by a novel calpain inhibitor in aged 3xTgAD mice with well-establis

166 overexpress human calpastatin, an endogenous calpain inhibitor, in skeletal muscle were produced.

167 nase (CaMK) type IV, which was attenuated by calpain inhibitors, in GCs supplemented with 20 mm KCl.

168 Cell-permeable calpain inhibitors, including calpastatin and calpeptin,

169 Studies using specific caspase or calpain inhibitors indicate that the pattern of spectrin

170 Studies with a selective membrane permeable calpain inhibitor indicated that tTG is likely to be an

171 illomavirus E6 protein was unaffected by the calpain inhibitor, indicating that the stabilization did

172 Calpain inhibitors inhibited the cleavage of the beta3 c

173 modulin kinase, and calpain inhibitor III, a calpain inhibitor, inhibited NMDA-induced potentiation a

174 , indicating that inhibition of apoptosis by calpain inhibitors is independent of effects on viral re

175 apoptosis, indicating that the effect of the calpain inhibitors is not due to cross-inhibition of lys

176 nsulin secretion with short-term exposure to calpain inhibitors is not mediated by increased response

177 vage is inhibited by calpeptin, calpastatin, calpain inhibitor IV, and E-64d, but not by caspase 3 in

178 of p107 protein which was reversible by the calpain inhibitor leucyl-leucyl-norleucinal but not by t

179 These calpain inhibitors limited epidermal growth factor-induc

180 Calpain inhibitors may therefore be useful therapeutical

181 hich was attenuated by pretreatment with the calpain inhibitor MDL-28170 or by transgenic overexpress

182 These effects were blocked by the calpain inhibitor MDL-28170.

183 uct immunoreactivity could be blocked by the calpain inhibitor MDL28,170 and appeared in neuronal cel

184 Addition of the calpain inhibitors MDL28,170, calpain inhibitors I and I

185 n of Akt in ASMCs, which were blocked by the calpain inhibitor MDL28170.

186 The calpain inhibitor, MDL28170, significantly improved the

187 Here, we report that treatment with the calpain inhibitor N-[N-(N-acetyl-l-leucyl)-l-leucyl]-l-n

188 uced NF-kappaB activation was blocked by the calpain inhibitor N-Ac-Leu-Leu-norleucinal, suggesting t

189 Exposure of preadipocytes to the calpain inhibitor N-acetyl-Leu-Leu-norleucinal or overex

190 The calpain inhibitor N-acetyl-leucyl-leucyl-norleucinal (AL

191 Calpain inhibitor N-acetyl-leucyl-leucyl-norleucinal blo

192 Calpain inhibitors N-acetyl-leu-leu-norleucinal (ALLN) a

193 We found that the calpain inhibitors N-acetyl-leu-leu-norleucinal (calpain

194 ocarbamate), Ca(2+) chelator (BAPTA-AM), and calpain inhibitor (N-acetyl-Leu-Leu-Met-H).

195 lator, 3,4,5-trimethoxybenzoic acid, and the calpain inhibitor, N-acetyl-Leu-Leu-norleucinal, both bl

196 The calpain inhibitor, N-acetyl-leucyl-leucyl-methional, or

197 Surprisingly, calpeptin was the only calpain inhibitor of several tested with the ability to

198 ressing calpastatin, the specific endogenous calpain inhibitor, on the activity of the two proteolyti

199 Studies utilizing Calpain inhibitors or Calpain-deficient cells confirm th

200 S activity in HAECs, which were prevented by calpain inhibitors or mu-calpsiRNA.

201 k but were blocked fully by the irreversible calpain inhibitor PD150606.

202 microM), a potent calmodulin inhibitor, and calpain inhibitor peptide (CIP, 10 microM) protected neu

203 Treating diabetic mice with a calpain inhibitor prevented loss of platelet dicer as we

204 The calpain inhibitor prevented proteoglycan loss, but the p

205 Calpastatin, a specific calpain inhibitor prevented the effects of calpain I on

206 Calpain inhibitors prevented cleavage of Bid as well as

207 Cell-permeable calpain inhibitors prevented E-cad(100) induction by ion

208 lines were established that overexpress the calpain inhibitor protein, calpastatin, under control of

209 inhibitor, calpeptin, or the highly specific calpain inhibitor protein, calpastatin.

210 Calpain inhibitors reduced IL-1alpha release and MCP-1 u

211 ated AR, and treatment of these cells with a calpain inhibitor reduces truncated AR expression.

212 Calpain inhibitors rescued HHcy- and HHcy/HG-induced ED

213 calpain-knockout mice or rats treated with a calpain inhibitor resulted in prevention of increased ri

214 Co-treatment with calpain inhibitors resulted in preservation of titin, re

215 Finally, the use of isoform-selective calpain inhibitors revealed that calpain-2 was involved

216 In contrast, animals pretreated with the calpain inhibitor showed minimal evidence of apoptosis.

217 Calpain inhibitor SJA6017 may have potential for testing

218 e-3 and could be completely inhibited by the calpain inhibitor SJA6017, implicating both calpain and

219 ted calpain, and reduction of cell damage by calpain inhibitor SJA6017.

220 he retinal cells treated with 10 and 100 muM calpain inhibitor SNJ-1945.

221 Calpain inhibitors suppressed NF-kappaB activation via i

222 ketophosphonates 1c,e,f are much less potent calpain inhibitors than dimethyl alpha-ketophosphonate 1

223 Both aLLN and PD150606, a specific calpain inhibitor that interacts with the calcium-bindin

224 In the presence of a calpain inhibitor, the apoptosis-inducing activity of PS

225 Intraperitoneal injection of a short term calpain inhibitor to timed pregnant female mice abrogate

226 otoxins (e.g., cisplatin, CDDP), the role of calpain inhibitors under these conditions was examined i

227 ects of the calpain inhibitors calpeptin and calpain inhibitor V.

228 vo treatment with the calpastatin peptide, a calpain inhibitor, was strongly neuroprotective in mice

229 Using proteasome and calpain inhibitors, we determined that the basal activit

230 These beneficial effects of the calpain inhibitors were associated with restoration of n

231 4 as a lead, three successive generations of calpain inhibitors were developed using computationally

232 Rac or Rho, respectively, occurred even when calpain inhibitors were present.

233 ations of calpastatin, a naturally occurring calpain inhibitor, were protective.

234 This effect was also seen with other calpain inhibitors with different mechanisms of action b

235 As nanomolar calpain inhibitors with promising selectivity and low to

236 product identified as a potent nonselective, calpain inhibitor, with demonstrated efficacy in animal

237 Some compounds acted as specific calpain inhibitors, with comparable activity on both cal

238 therefore hypothesized that treatment with a calpain inhibitor would protect neurons from immune-medi

239 e inhibited by the dipeptide alpha-ketoamide calpain inhibitor Z-Leu-aminobutyric acid-CONH(CH(2))3-m

240 Six animals were administered calpain inhibitor (Z-Leu-Leu-Tyr-fluoromethyl ketone; 1

241 itor), N-acetyl-leucyl-leucyl-norleucinal (a calpain inhibitor), z-VAD-fmk (a pan-caspase inhibitor),

242 Calpain inhibitors ZLLYCHN2, MDL 28170, and PD 150606 bl